Plasma p-Tau217 Set to Transform Alzheimer’s Diagnostics Could Common Vaccines Protect Against Alzheimer’s Disease? Doubling Down on Sequencing Serves up More Alzheimer’s Genes IDEAS Finds Small Drop in Hospitalizations, Missing Goal Lancet Commission’s ...
BANish Aβ? BAN2401 Antibody Makes Its Move in Phase 3 Program BAN2401 Forges AHEAD into Phase 3, Preclinical AD TRC-PAD Funnel Finally Touches Down Learning Troubles Spied by Smartphone Track with Biomarkers In Phase 2 Trial, Neflamapimod Aids Cognition ...
Merged Consortia Forge Path to Trials in Frontotemporal Dementia FTD Fluid Markers for Degeneration: Check. For Pathology: Not Yet. Imaging Exposes Hugely Heterogeneous Brain Changes Among FTDs Moving Target: Can Standardized Tests Track Symptoms of FTD? ...
Donanemab Confirms: Clearing Plaques Slows Decline—By a Bit Astroglial Markers Poised for Stardom? Shuttle Unloads More Gantenerumab Into the Brain N-Terminal Tau Antibodies Fade, Mid-Domain Ones Push to the Fore Where to Now, Phospho-Tau? Clinicians from ...
Amber Dance Interviews Stephen Cohen
Amber Dance Interviews Ken Kosik
Alisa Woods Interviews Murali Doraiswamy and Lisa Gwyther
Tom Fagan Interviews Deborah Blacker
Pat McCaffrey Interviews Randy Buckner
Tom Fagan Interviews Rudy Tanzi and Lars Bertram
Tom Fagan Interviews Howard Fillit
Tom Fagan Interviews Bud Kukull
Gabrielle Strobel Interviews Martin Citron
Gabrielle Strobel Interviews John Morris
Gabrielle Strobel Interviews Sheldon Goldberg